Trousseau’s syndrome caused by bladder cancer producing granulocyte colony-stimulating factor and parathyroid hormone-related protein: A case report

Keyphrases

• Granulocyte Colony-stimulating Factor (G-CSF) 100%
• Bladder Cancer 100%
• Parathyroid Hormone-related Protein (PTHrP) 100%
• Trousseau Syndrome 100%
• Tumor 33%
• Lymph Node Metastasis 33%
• Computed Tomography 33%
• Tumor Marker 33%
• Carbohydrate Antigen 19-9 (CA19-9) 33%
• Systemic Chemotherapy 33%
• Old Japanese 33%
• Hypointense 33%
• Female Patients 33%
• Japanese Females 33%
• Protein Production 33%
• Lower Limb Strength 33%
• Carcinoembryonic Antigen 33%
• Positive Staining 33%
• Heparin 33%
• Transurethral Resection of Bladder Tumor (TURBT) 33%
• Gemcitabine Plus Cisplatin 33%
• Sudden Onset 33%
• Squamous Cell Carcinoma Antigen 33%
• Hypercalcemia 33%
• Carbohydrate Antigen 125 (CA125) 33%
• Occult 33%
• Initial Symptom 33%
• Thromboembolism 33%
• Repeated Administration 33%
• Bladder Tumor 33%
• Antigen Levels 33%
• Leukocytosis 33%
• Multi-regional 33%
• Paraneoplastic Syndrome 33%
• Venous Thrombosis 33%
• Malignancy-associated 33%
• Acute Cerebral Infarction 33%
• Arterial Thrombosis 33%
• Visual Field Defect 33%
• Cerebral Magnetic Resonance Imaging 33%
• Abdominal Malignancy 33%
• Hypercoagulative State 33%
• Urothelial Cell Carcinoma 33%
• Anticoagulant Treatment 33%
• CYFRA 21-1 33%

Medicine and Dentistry

• Disease 100%
• Granulocyte Colony Stimulating Factor 100%
• Bladder Cancer 100%
• Parathyroid Hormone-Related Protein 100%
• Protein A 100%
• Cancer 66%
• Thromboembolism 66%
• Bladder Tumor 66%
• Lymph Node Metastasis 33%
• Neoplasm 33%
• Brain Infarction 33%
• Computer Assisted Tomography 33%
• Magnetic Resonance Imaging 33%
• Transitional Cell Carcinoma 33%
• Tumor Marker 33%
• Cisplatin 33%
• CA 19-9 Antigen 33%
• Carcinoembryonic Antigen 33%
• Transurethral Resection 33%
• Gemcitabine 33%
• Lower Limb 33%
• Heparin 33%
• Anticoagulant Therapy 33%
• Phlebothrombosis 33%
• Hypercalcaemia 33%
• Repeated Drug Dose 33%
• Tumor Antigen 33%
• Artery Thrombosis 33%
• Limb Weakness 33%
• Squamous Cell Carcinoma Antigen 33%
• Leukocytosis 33%
• Visual Field Defect 33%
• Cytokeratin 19 Fragment 33%
• Chemotherapy 33%